The cost of relapse in schizophrenia and schizoaffective disorder

Australasian Psychiatry

Volumn 17, Issue 4, 2009, Pages 265-272

  Fitzgerald, Paul ^a   De Castella, Anthony ^a   Arya, Dinesh ^b   Simons, W Robert ^c   Eggleston, Andrew ^d   Meere, Sharon ^d   Kulkarni, Jayashari ^a  

^a MONASH UNIVERSITY   (Australia)

^b Hawke's Bay District Health Board   (Australia)

^c Global Health Economics and Outcomes Research Inc   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Health economics; Relapse; Schizoaffective disorder; Schizophrenia

Indexed keywords

ADULT; ARTICLE; COST OF ILLNESS; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MENTAL HEALTH SERVICE; MENTAL PATIENT; RELAPSE; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; ADOLESCENT; AGED; AUSTRALIA; ECONOMICS; LENGTH OF STAY; LONGITUDINAL STUDY; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; PSYCHOSIS; RECURRENT DISEASE; STATISTICAL ANALYSIS;

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; AUSTRALIA; COST OF ILLNESS; DATA INTERPRETATION, STATISTICAL; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 70249109754     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1080/10398560903002998     Document Type: Article

References (17)

1. Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Australian and New Zealand Journal of Psychiatry 2003; 37: 31-40.
2. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clinical Therapeutics 1997; 19: 1470-1495; discussion 1424-1475.
3. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 2001; 52: 805-811.
4. Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. British Journal of Psychiatry 2003; 183: 427-435; discussion 436.
5. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM, Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services 1997; 48: 1571-1577. (Pubitemid 27512385)
6. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry 1999; 156: 863-868.
7. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. British Journal of Psychiatry 1998; 172: 499-505.
8. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. American Journal of Psychiatry 2001; 158: 266-269.
9. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. British Journal of Psychiatry 2004; 184: 346-351.
10. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. British Journal of Psychiatry 1993; 162: 38-42.
11. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. American Journal of Managed Care 1998; 4: 345-355.
12. Rosenheck R, Chang S, Choe Y et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry 2000; 61: 382-386.
13. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin 1995; 21: 419-429.
14. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Journal of Clinical Psychiatry 1996; 57: 337-345.
15. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services 2003; 54: 508-516.
16. Lieberman JA, Koreen AR, Chakos M et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Journal of Clinical Psychiatry 1996; 57 (Suppl. 9): 5-9.
17. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophrenia Bulletin 1998; 24: 75-85.